Evidence map›Paper›PMID 32563849›Full record

ArticleCellular immunology2020

Surviving the storm: Dealing with COVID-19.

Arthur A Vandenbark, Roberto Meza-Romero, Halina Offner

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arthur A VandenbarkNeuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA; Department of Molecular Microbiology & Immunology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA. Electronic address: vandenba@ohsu.edu.
Roberto Meza-RomeroNeuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
Halina OffnerNeuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA; Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.

Funding

Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjectsR44AI122574 · NIAID · VIROGENOMICS BIODEVELOPMENT, INC. · PI SHIRLEY, RENEE LYNN, VANDENBARK, ARTHUR A. · 2020 to 2022
$3.0M
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjectsR41AI122574 · NIAID · VIROGENOMICS BIODEVELOPMENT, INC. · PI VANDENBARK, ARTHUR A. · 2016 to 2016
$225k
Immunoregulation of Myelin-Specific T LymphocytesI01BX000226 · VA · PORTLAND VA MEDICAL CENTER · PI VANDENBARK, ARTHUR A. · 2009 to 2024
–
Preclinical Translational Studies with DRHQI01BX005112 · VA · PORTLAND VA MEDICAL CENTER · PI VANDENBARK, ARTHUR A. · 2020 to 2024
–
BLRD Research Career Scientist Award ApplicationIK6BX004209 · VA · PORTLAND VA MEDICAL CENTER · PI ARTHUR A. VANDENBARK · 2018 to 2026
–
BLRD VA I01 BX000226BLRD VA I01 BX005112BLRD VA IK6 BX004209NIAID NIH HHS R41 AI122574NIAID NIH HHS R44 AI122574
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigens, Differentiation, B-LymphocyteAnti-Inflammatory AgentsBetacoronavirusCoronavirus InfectionsCOVID-19Cytokine Release SyndromeHistocompatibility Antigens Class IIHLA-DR alpha-ChainsHumansMyelin-Oligodendrocyte GlycoproteinPandemicsPneumonia, ViralReceptors, Antigen, T-CellRecombinant ProteinsSARS-CoV-2Antigens, Differentiation, B-LymphocyteAnti-Inflammatory AgentsDRhQHistocompatibility Antigens Class IIHLA-DR alpha-Chainsinvariant chainMOG protein, humanMyelin-Oligodendrocyte GlycoproteinReceptors, Antigen, T-CellRecombinant Proteins

Identifiers

PMID32563849
PMCPMC7293470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.